Meijuan Fang

机构：Xiamen University · ORCID：0000-0002-3205-9037

发表论文 156 篇 · 总被引 2739 次 · h-index 27

代表论文

• Global trends in colorectal cancer and metabolic syndrome research: a bibliometric and visualization analysis (2024 · International Journal of Surgery · 被引 29)
• Discovery of 5-(Pyrimidin-2-ylamino)-1 H -indole-2-carboxamide Derivatives as Nur77 Modulators with Selective and Potent Activity Against Triple-Negative Breast Cancer (2023 · Journal of Medicinal Chemistry · 被引 20)
• Design, synthesis, and biological evaluation of novel 4,4′-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer (2023 · European Journal of Medicinal Chemistry · 被引 18)
• Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors (2023 · European Journal of Pharmacology · 被引 11)
• The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma (2023 · British Journal of Cancer · 被引 10)
• Discovery of a novel exceptionally potent and orally active Nur77 ligand NB1 with a distinct binding mode for cancer therapy (2024 · Acta Pharmaceutica Sinica B · 被引 9)